Roswell Park Cancer Institute (RPCI) requests renewal of its National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) for years 27-31. This application reflects significant changes in leadership, faculty, programmatic and scientific direction, facilities and governance over the past few years. RPCI has, under the leadership of David C. Hohn, MD, President and CEO, recruited new senior leaders for basic, clinical, translational and population science. The CCSG scientific enterprise has been consolidated into five programs and 14 shared resources. These CCSG Programs now include Therapeutics, Biophysical Therapies, Tumor Immunology, Genetics and Cancer Prevention; four of these programs are under new leadership. The Institute has increased its scientific capabilities through the recruitment of 43 new members to CCSG Programs in both the laboratory and clinical research areas. With these recruitments and existing strength, peer-reviewed grant funding has significantly increased in the past year. RPCI and programmatic strategic planning has generated an overall Institute strategy for growth and direction with programmatic strategies targeted toward scientific excellence and multidisciplinary approaches. The overall vision of RPCI over the next five years will focus on the identification, validation and exploitation of targets for cancer treatment and control based on substantial inter-programmatic efforts from all of the Programs. To accommodate the growth of the CCSG membership, development of a new 170,000 gross square feet basic research laboratory building is underway and will be finished by 2005. We are requesting $3.0 million which will support five scientific programs, 14 shared resources, leadership, developmental funds, planning and evaluation and administration. Recruitment, reorganization and institutional commitment have reinvigorated RPCI as a comprehensive cancer center with focused vision for the future and for the development of excellence in all aspects of cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-30
Application #
7060479
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2008-04-30
Budget Start
2006-05-10
Budget End
2007-04-30
Support Year
30
Fiscal Year
2006
Total Cost
$3,799,480
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Leonova, Katerina; Safina, Alfiya; Nesher, Elimelech et al. (2018) TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife 7:
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061

Showing the most recent 10 out of 1555 publications